Authors
Latest:
Dr. Ferris on Significance of CheckMate-141 Trial for Head and Neck CancerRobert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).
Latest:
Expert Discusses Neoadjuvant Treatment Potential in Advanced RCCNeoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.
Latest:
Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCCNaomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).
Latest:
Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard TherapyAccording to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.
Latest:
Study Finds Hyperprogression After Immunotherapy in NSCLC SubsetAlthough anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.
Latest:
Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCLLenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.
Latest:
New Hairy Cell Leukemia Therapy Aims to Produce Complete RemissionsRobert J. Kreitman, MD, discusses key attributes of moxetumomab pasudotox and its potential impact in hairy cell leukemia.
Latest:
Dr. Lugtenburg on Maintenance Rituximab in DLBCLPieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell LeukemiaAgnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Latest:
Renal Cell Carcinoma Vaccine Fails to Improve OutcomesThe IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.
Latest:
Dr. Crinò on Crizotinib in ALK-Positive NSCLCLucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
Latest:
Dr. Normanno on Using Circulating Tumor DNA for EGFR DetectionNicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk NeuroblastomaInvestigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.
Latest:
The Virtual Window: Clinical Trial Reports--April 2007The Clinical Trials reported in this issue include: PHASE I: 1) Cell Genesys and Medarex Remain Positive on Combination Immunotherapy Study 2) Active Biotech Achieves Success with TASQ for Prostate Cancer PHASE II: 1) Myriad Initiates Evaluation of Brain Cancer Drug that Crosses the Blood-Brain Barrier 2) Second Lung Cancer Trial Adds Data to Novel Therapy, and more
Latest:
Best Initial Treatment Strategies for EGFR-Mutant Lung CancerThis review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.
Latest:
Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: Before We Accept This Treatment Paradigm, Let's Critically Evaluate and Interpret the DataNon-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.
Latest:
Why Oncology Can Be a Tough Sell in MaineChimeric antigen receptor T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia.
Latest:
Investigators Seek Expanded Use of Checkpoint Inhibitors in RCCIn contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.
Latest:
Axitinib Nears Approval as Second-Line Therapy for Metastatic Renal Cell CarcinomaAxitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.
Latest:
Robotic Surgery Is Useful Option for Oral CancerMinimally invasive transoral robotic surgery, used alone or combined with adjuvant therapy, provides good functional and oncologic outcomes in patients with oropharyngeal squamous cell carcinoma.
Latest:
Therapy of Non-Small Cell Lung Cancer: Past, Present, and FutureNew and relevant studies are examining the role of histology, biomarkers, and growth factor receptor inhibitors in the treatment of NSCLC.
